10 principais biospace.com concorrentes

fiercebiotech.com

A central nervous system (CNS) tumor has prompted the FDA to

biopharmadive.com

The latest pharma news for biotech and biopharmaceutical professionals

fiercepharma.com

|

statnews.com

Subscribe to First Opinion, a weekly health care podcast and The Readout Loud, a weekly biotech podcast.

firstwordpharma.com

Stay updated with the latest news, insights, and analysis from FirstWord PHARMA. FirstWord PHARMA provides comprehensive coverage of key developments and trends.

clinicaltrials.gov

ClinicalTrials.gov is a website and online database of clinical research studies and information about their results

globenewswire.com

globenewswire helps you share news with media, investors, and consumers using targeted distribution options. build awareness, boost online visibility, and get more media coverage.

pharmexec.com

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

bioworld.com

The opioid crisis may not be front and center anymore, but it’s raging still. A major problem is that overdose-reversal drugs don’t last long enough to help users who opt out of hospital treatment after they are revived. Elysium Therapeutics Inc. CEO Greg Sturmer talks with Randy Osborne about his firm’s candidate for a solution to the medical and societal problem. The NIH – which has been helpful to Elysium since the company’s founding – the FDA, and others are working to advance a longer-lasting reversal agent. Experiments already done with approved reversers, as well as computer modeling that’s been used by regulators previously, will help in the push, Sturmer said. Download transcript

thepharmaletter.com

The latest Pharma and Biotech News - The Pharma Letter